lupus.bmj2d
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors
Objective Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by a loss of immune tolerance, affecting ...
lupus.bmj4d
Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience
Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology that can affect almost any ...
lupus.bmj14h
1112 Change in urinary biomarkers at three months predicts 1-year treatment response of lupus nephritisbetter than proteinuria
Intro/Background A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR < 0.5 defines complete ...
lupus.bmj9y
Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...
lupus.bmj7d
Patient-reported outcome measures for use in clinical trials of SLE: a review
Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare ...
lupus.bmj11d
Exacerbating effects of circadian rhythm disruption on the systemic lupus erythematosus
Objective Circadian rhythm disruption (CRD) has been associated with inflammation and immune disorders, but its role in SLE progression is unclear. We aimed to investigate the impact of circadian ...
lupus.bmj11d
Cell-bound complement activation products associate with lupus severity in SLE
Objectives To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. Methods All subjects (n=495) fulfilled the ...
lupus.bmj7d
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
3 Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA 4 Division of Rheumatology, Allergy and Immunology, University of California San ...
lupus.bmj13d
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases
Objective Systemic autoimmune rheumatic diseases (SARDs) encompass a diverse group of complex conditions with overlapping clinical features, making accurate diagnosis challenging. This study aims to ...
lupus.bmj13d
O7 Safety of chloroquine and hydroxychloroquine during pregnancy: a systematic literature review and meta-analysis
Background Some countries face restrictions to prescribe Chloroquine (CQ) and Hydroxychloroquine (HCQ) during pregnancy, due to report of ocular toxicity in rodents and potential genotoxicity. The aim ...
lupus.bmj8d
Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
lupus.bmj11d
29 Treatment of CAPS: which drugs and in which order?
Describe why combination of anticoagulation and corticosteroids is the cornerstone treatment of CAPS and that life-threatening CAPS episodes should be treated with a triple-therapy including ...